Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., announced a partnership with Harrow to launch an authorized generic of Maxitrol (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension), which treats and relieves bacterial eye infections.

Maxitrol and generic equivalents had annual sales of $20.8 million in the United States, according to IQVIA data, as of January 2025.

"Today marks the culmination of months of work to bring this exciting new authorized generic to the marketplace," said Thomas Sammler, Nordic Pharma's VP commercial operations, in a company press release. "This product is a great addition to our generic portfolio, providing patients another affordable prescription option."